Andrea Estébanez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Andrea Estébanez has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
- Esmeralda Silva Díaz
Servicio de Dermatología, Hospital Clínico Universitario de Valencia, Valencia, España
9 shared publications Carlos Monteagudo
Department of Pathology Clinical University Hospital University of Valencia Valencia Spain
4 shared publicationsAna Cuesta
Department of Genetics Clinical University Hospital University of Valencia Valencia Spain
3 shared publications- Francisco Javier Melgosa Ramos
Department of dermatology, hospital Lluís Alcanyís, Xátiva, Valencia, Spain
3 shared publications Jose M. Martín
Department of Dermatology Clinical University Hospital University of Valencia Valencia Spain
3 shared publications- Andrés Casanova Esquembre
Departamento de Dermatología, Consorcio Hospital General Universitario de Valencia, España
2 shared publications
Latest Publications
- 30 May 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (11)
Anifrolumab for lupus erythematosus in real‐world practice: A Spanish national series
- 30 May 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (11)
Anifrolumab for lupus erythematosus in real‐world practice: A Spanish national series
- Open Access
- 11 August 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (16) , 5683
Anifrolumab for Nonsystemic Cutaneous Lupus Erythematosus: Clinical Experience, Immunologic Insights, and Review of the Literature
Objective: Anifrolumab is approved for systemic lupus erythematosus (SLE). Its off-label use in non-systemic cutaneous lupus erythematosus (NSCLE) remains poorly characterized. We aimed to assess its effectiveness and safety in refractory NSCLE, supported by a literature review and exploratory immunologic analysis. Methods: This multicenter observational study included patients with NSCLE treated with anifrolumab. Skin disease was assessed using the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI). CLASI scores at baseline were compared to months 1, 3, and 6. A narrative literature review was also conducted. In a subset of three patients, peripheral blood immunophenotyping was performed before and after treatment to explore immunologic surrogate markers associated with clinical response. Results: Fifteen patients (11 women; mean age 52.1 ± 11.7 years) were included. All had received topical corticosteroids and hydroxychloroquine. Most of them had failed multiple systemic therapies. Anifrolumab (300 mg IV every 4 weeks) was used in combination (n = 12) or as monotherapy (n = 3). All patients improved. Median CLASI-A decreased from 16 to 1 (p < 0.001); CLASI-D decreased from 5 to 4 (p < 0.001). The literature review identified 6 publications reporting 14 additional cases of NSCLE with similar outcomes and minimal adverse effects. Immunologic profiling pointed to an increase in intermediate and non-classical and decreased PD-1 expression in monocytes and NK cells after 12 weeks of treatment. Conclusions: Anifrolumab appears effective and relatively safe in refractory NSCLE. Preliminary immunologic data suggest changes in peripheral blood monocyte subsets and NK cells. However, these findings must be confirmed in prospective, controlled clinical trials.
- 11 August 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (16) , 5683
Open AccessAnifrolumab for Nonsystemic Cutaneous Lupus Erythematosus: Clinical Experience, Immunologic Insights, and Review of the Literature
Objective: Anifrolumab is approved for systemic lupus erythematosus (SLE). Its off-label use in non-systemic cutaneous lupus erythematosus (NSCLE) remains poorly characterized. We aimed to assess its effectiveness and safety in refractory NSCLE, supported by a literature review and exploratory immunologic analysis. Methods: This multicenter observational study included patients with NSCLE treated with anifrolumab. Skin disease was assessed using the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI). CLASI scores at baseline were compared to months 1, 3, and 6. A narrative literature review was also conducted. In a subset of three patients, peripheral blood immunophenotyping was performed before and after treatment to explore immunologic surrogate markers associated with clinical response. Results: Fifteen patients (11 women; mean age 52.1 ± 11.7 years) were included. All had received topical corticosteroids and hydroxychloroquine. Most of them had failed multiple systemic therapies. Anifrolumab (300 mg IV every 4 weeks) was used in combination (n = 12) or as monotherapy (n = 3). All patients improved. Median CLASI-A decreased from 16 to 1 (p < 0.001); CLASI-D decreased from 5 to 4 (p < 0.001). The literature review identified 6 publications reporting 14 additional cases of NSCLE with similar outcomes and minimal adverse effects. Immunologic profiling pointed to an increase in intermediate and non-classical and decreased PD-1 expression in monocytes and NK cells after 12 weeks of treatment. Conclusions: Anifrolumab appears effective and relatively safe in refractory NSCLE. Preliminary immunologic data suggest changes in peripheral blood monocyte subsets and NK cells. However, these findings must be confirmed in prospective, controlled clinical trials.
- Open Access
- 30 May 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 100 (3) , 566-569
Eficácia e segurança em médio prazo e potenciais preditores de resposta ao upadacitinibe em pacientes com dermatite atópica moderada a grave: estudo retrospectivo observacional multicêntrico
- 30 May 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 100 (3) , 566-569
Open AccessEficácia e segurança em médio prazo e potenciais preditores de resposta ao upadacitinibe em pacientes com dermatite atópica moderada a grave: estudo retrospectivo observacional multicêntrico
- Open Access
- 21 April 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 100 (3) , 566-569
Mid-term effectiveness, safety, and potential predictors of response of upadacitinib in patients with moderate-to-severe atopic dermatitis: a multicenter observational retrospective study
- 21 April 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 100 (3) , 566-569
Open AccessMid-term effectiveness, safety, and potential predictors of response of upadacitinib in patients with moderate-to-severe atopic dermatitis: a multicenter observational retrospective study
- 29 October 2022
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 37 (4) , E517-E519
Long‐term secukinumab efficacy in patients with moderate to severe hidradenitis suppurativa: A retrospective single‐centre case series (23 patients)
- 29 October 2022
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 37 (4) , E517-E519
Long‐term secukinumab efficacy in patients with moderate to severe hidradenitis suppurativa: A retrospective single‐centre case series (23 patients)
- Open Access
- 2 August 2021
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 34 (5) , e15074
Characteristics of mucocutaneous vascular malformations drawn from a decade of a multidisciplinary committee experience
Vascular malformations (VM) are congenital, benign, and relatively frequent lesions. Scant data have been published about the epidemiology, clinical presentation, and treatment of VM from a dermatologist's perspective. The substantial differences between subtypes, broad range of specialists consulted and confusing nomenclature used over previous years may hamper a correct diagnosis. The main objective of this study is to describe VM epidemiology. As a secondary endpoint we evaluate clinical characteristics, clinical-radiological correlation and treatment approaches. We carried out an observational, descriptive, retrospective study. Cases presented to the multidisciplinary committee of our hospital from 2009 to 2019 were retrieved. Electronic medical records, monthly committee reports and the iconographic archive were reviewed and statistically analyzed. Overall, venous malformations (VeM) are the most frequent VM, followed by capillary malformations (CM), arterioVeM and lymphatic malformations (LM). Considering only patients under 16, CMs are the most frequent ones. Capillary and LMs are larger than venous or arteriovenous. While CMs are usually asymptomatic, symptomatic cases are threefold more frequent in the other subtypes. Decisions on active or conservative management depend on VM size but not location or patient age. CMs are mainly treated with laser therapy; venous with sclerotherapy or surgery; arteriovenous with surgery and lymphatic with surgery or sirolimus. Dermatologists play an important role in VM diagnosis and management. Our 10-year multidisciplinary experience should contribute to the literature and represent a practical resource for clinicians and researchers.
- 2 August 2021
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 34 (5) , e15074
Open AccessCharacteristics of mucocutaneous vascular malformations drawn from a decade of a multidisciplinary committee experience
Vascular malformations (VM) are congenital, benign, and relatively frequent lesions. Scant data have been published about the epidemiology, clinical presentation, and treatment of VM from a dermatologist's perspective. The substantial differences between subtypes, broad range of specialists consulted and confusing nomenclature used over previous years may hamper a correct diagnosis. The main objective of this study is to describe VM epidemiology. As a secondary endpoint we evaluate clinical characteristics, clinical-radiological correlation and treatment approaches. We carried out an observational, descriptive, retrospective study. Cases presented to the multidisciplinary committee of our hospital from 2009 to 2019 were retrieved. Electronic medical records, monthly committee reports and the iconographic archive were reviewed and statistically analyzed. Overall, venous malformations (VeM) are the most frequent VM, followed by capillary malformations (CM), arterioVeM and lymphatic malformations (LM). Considering only patients under 16, CMs are the most frequent ones. Capillary and LMs are larger than venous or arteriovenous. While CMs are usually asymptomatic, symptomatic cases are threefold more frequent in the other subtypes. Decisions on active or conservative management depend on VM size but not location or patient age. CMs are mainly treated with laser therapy; venous with sclerotherapy or surgery; arteriovenous with surgery and lymphatic with surgery or sirolimus. Dermatologists play an important role in VM diagnosis and management. Our 10-year multidisciplinary experience should contribute to the literature and represent a practical resource for clinicians and researchers.
- 17 June 2021
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 19 (6) , 906-908
Kutane und systemische Veränderungen mit Ähnlichkeiten zum Omenn‐Syndrom bei heterozygoter Mutation im RAG2‐Gen
- 17 June 2021
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 19 (6) , 906-908
Kutane und systemische Veränderungen mit Ähnlichkeiten zum Omenn‐Syndrom bei heterozygoter Mutation im RAG2‐Gen
- 7 June 2021
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 19 (6) , 906-908
A heterozygous mutation in the RAG2 gene with cutaneous and systemic manifestations partially resembling Omenn syndrome
- 7 June 2021
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 19 (6) , 906-908
A heterozygous mutation in the RAG2 gene with cutaneous and systemic manifestations partially resembling Omenn syndrome
- Open Access
- 1 July 2020
- Published by Elsevier in Anales de Pediatría
- Vol. 93 (1) , 49-50
Síndrome de Gianotti-Crosti-like secundario a Molluscum contagiosum
- 1 July 2020
- Published by Elsevier in Anales de Pediatría
- Vol. 93 (1) , 49-50
Open AccessSíndrome de Gianotti-Crosti-like secundario a Molluscum contagiosum